PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $4.3333.

A number of analysts recently weighed in on PMVP shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of PMV Pharmaceuticals in a research report on Friday, September 4th. Weiss Ratings cut PMV Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Finally, LADENBURG THALM/SH SH assumed coverage on PMV Pharmaceuticals in a report on Wednesday, July 8th. They issued a “buy” rating and a $3.00 price target on the stock.

PMV Pharmaceuticals Stock Up 4.7%

PMVP stock opened at $1.44 on Friday. PMV Pharmaceuticals has a twelve month low of $1.02 and a twelve month high of $1.88. The stock has a market capitalization of $76.98 million, a price-to-earnings ratio of -1.01 and a beta of 1.37. The firm’s fifty day simple moving average is $1.26 and its two-hundred day simple moving average is $1.30.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.05. As a group, equities research analysts expect that PMV Pharmaceuticals will post -1.26 EPS for the current year.

Key PMV Pharmaceuticals News

Here are the key news stories impacting PMV Pharmaceuticals this week:

• Positive Sentiment: PMV appointed Philip Herman as chief commercial officer ahead of a planned rezatapopt filing. The hire signals that management is preparing for potential commercialization and could improve investor confidence in the program’s development path. PMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt Filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $5.00 price target, substantially above the recent trading level. The firm projects improving losses, including a reduction from an estimated $1.03 per share loss in fiscal 2026 to $0.61 in fiscal 2027, although it still expects PMVP to remain unprofitable. HC Wainwright PMV Pharmaceuticals analyst estimates
• Positive Sentiment: Separate analyst coverage placed the average target price at $4.33, reinforcing the view that the stock could have significant upside if rezatapopt advances successfully. Analysts Set PMV Pharmaceuticals Target Price at $4.33
• Neutral Sentiment: The reported September short-interest figure was zero shares, unchanged from the prior report, with a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering or bearish positioning and may reflect a reporting-data issue.
• Neutral Sentiment: A broader analyst roundup included PMV Pharmaceuticals but provided no additional specific rating or estimate changes. Analysts Offer Insights on Healthcare Companies

Hedge Funds Weigh In On PMV Pharmaceuticals

Several hedge funds have recently bought and sold shares of PMVP. Shay Capital LLC bought a new stake in shares of PMV Pharmaceuticals during the second quarter worth $26,000. Vanguard Group Inc. grew its holdings in shares of PMV Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 2,163,027 shares of the company’s stock worth $3,028,000 after purchasing an additional 9,427 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in PMV Pharmaceuticals by 115.5% in the 3rd quarter. Bridgeway Capital Management LLC now owns 320,653 shares of the company’s stock worth $449,000 after buying an additional 171,853 shares during the period. Algert Global LLC purchased a new position in PMV Pharmaceuticals in the 3rd quarter worth about $87,000. Finally, Boothbay Fund Management LLC purchased a new position in PMV Pharmaceuticals in the 3rd quarter worth about $282,000. Institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.